News >

Progress Continues in HR+/HER2- Breast Cancer Paradigm

Brandon Scalea
Published: Tuesday, Mar 26, 2019

Kristin J. Richardson, MD

Kristin J. Richardson, MD

CDK4/6 inhibitors have been a practice-changing addition to the treatment armamentarium for patients with hormone receptor (HR)–positive metastatic breast cancer, said Kristin J. Richardson, MD. Now, investigators hope to move these agents into an earlier treatment setting.

There are currently 3 FDA-approved CDK4/6 inhibitors available for the treatment of patients with HR-positive, HER2-negative breast cancer: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). All 3 agents have shown consistent progression-free survival advantage across patient subgroups.

“I was starting my fellowship right when all of this was creating a big excitement in the field,” said Richardson, a hematology/oncology fellow at Rush University Medical Center. “I don’t know what things were like 20 years ago, but the more we can do to make it easier for the patient and improve their quality of life is wonderful to me.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x